Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Comment by Raddnaron Oct 26, 2020 2:00pm
115 Views
Post# 31782357

RE:RE:comments on Algernon progress....

RE:RE:comments on Algernon progress....Agreed. Sometimes I wonder if people comment these timelines to reassure themselves or to have a “I told you so” in the bag.

it does suck waiting, but I tell ya guys, if this was any other time, this would be at least a 2 year process. It’s very rare you get a low entry point pharma stock that’s this promising and have an assured 7 month turn around. Repurposing helps, but what’s doin most of the leg work is the response to covid. unfortunetly, we’re going to get A LOT of bad product put out on the market and it’s going to hurt companies and people regardless of the “no liability clauses” signed for operation warp speed. That’s why I love AGN. Ifenprodil has a 50 year track record of being safe. The only risk we’re taking is the bet if it’s effective at treating TWO conditions.

Normally, you’re sitting at a 4-8 year waiting period for a new drug that has investment risks with efficacy, safety and only treats ONE condition. Plus, you probably won’t get in early enough to take advantage of that early low priced entry point.

This goes to everyone, if this is your first long pharma investment, don’t just be patient, feel blessed. Things are looking great. This could be you big pay out depending on your investment size and at the bare minimum the easiest money you’ve ever made. 
<< Previous
Bullboard Posts
Next >>